CN112955447B - 杂环激酶抑制剂及其用途 - Google Patents

杂环激酶抑制剂及其用途

Info

Publication number
CN112955447B
CN112955447B CN201980069736.5A CN201980069736A CN112955447B CN 112955447 B CN112955447 B CN 112955447B CN 201980069736 A CN201980069736 A CN 201980069736A CN 112955447 B CN112955447 B CN 112955447B
Authority
CN
China
Prior art keywords
alkyl
compound
formula
group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980069736.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112955447A (zh
Inventor
彼得·森恩
塞巴斯蒂安·迈耶埃韦特
尼西特·坎德瓦尔
大卫·班克罗夫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aomax Treatment Co ltd
Original Assignee
Aomax Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aomax Treatment Co ltd filed Critical Aomax Treatment Co ltd
Publication of CN112955447A publication Critical patent/CN112955447A/zh
Application granted granted Critical
Publication of CN112955447B publication Critical patent/CN112955447B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CN201980069736.5A 2018-10-23 2019-10-22 杂环激酶抑制剂及其用途 Active CN112955447B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18202164.2A EP3643713B1 (en) 2018-10-23 2018-10-23 Heterocyclic kinase inhibitors and uses thereof
EP18202164.2 2018-10-23
PCT/EP2019/078751 WO2020083926A1 (en) 2018-10-23 2019-10-22 Heterocyclic kinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN112955447A CN112955447A (zh) 2021-06-11
CN112955447B true CN112955447B (zh) 2025-09-09

Family

ID=64270595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980069736.5A Active CN112955447B (zh) 2018-10-23 2019-10-22 杂环激酶抑制剂及其用途

Country Status (13)

Country Link
US (3) US12172993B2 (cg-RX-API-DMAC7.html)
EP (2) EP3643713B1 (cg-RX-API-DMAC7.html)
JP (1) JP7667568B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210081353A (cg-RX-API-DMAC7.html)
CN (1) CN112955447B (cg-RX-API-DMAC7.html)
AU (1) AU2019368654C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021007643A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116674A1 (cg-RX-API-DMAC7.html)
DK (1) DK3643713T3 (cg-RX-API-DMAC7.html)
IL (1) IL282588A (cg-RX-API-DMAC7.html)
MX (1) MX2021004568A (cg-RX-API-DMAC7.html)
SG (1) SG11202103142TA (cg-RX-API-DMAC7.html)
WO (1) WO2020083926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP3643713B1 (en) 2018-10-23 2025-07-30 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
EP3901151B1 (en) * 2020-04-21 2026-04-01 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
KR20220145393A (ko) * 2020-08-31 2022-10-28 닛폰세이테츠 가부시키가이샤 강판 및 그 제조 방법
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
WO2023067021A1 (en) * 2021-10-19 2023-04-27 Iomx Therapeutics Ag A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4643861B1 (en) 2024-04-30 2026-07-29 iOmx Therapeutics AG A halogenated heteroaryl kinase inhibitor for use in treating angiosarcoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534831A (zh) * 2006-09-11 2009-09-16 柯瑞斯公司 包含锌结合基因的取代的酪氨酸抑制剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
KR100919905B1 (ko) * 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9422262B2 (en) * 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
CA2877589C (en) * 2012-06-27 2019-11-26 4Sc Ag Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
CN106699744B (zh) 2015-11-18 2021-05-11 四川海思科制药有限公司 一种杂环类酰胺衍生物及其制备方法和在药学上的应用
EP3391907B8 (en) * 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
EP3643703A4 (en) 2017-06-21 2020-12-23 Daiichi Sankyo Co., Ltd. EP300 / CREBBP INHIBITOR
EP3643713B1 (en) 2018-10-23 2025-07-30 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
KR20230007398A (ko) 2020-04-21 2023-01-12 바이엘 악티엔게젤샤프트 해충 방제제로서 2-(헤트)아릴-치환된 축합 헤테로시클릭 유도체
WO2023067021A1 (en) 2021-10-19 2023-04-27 Iomx Therapeutics Ag A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534831A (zh) * 2006-09-11 2009-09-16 柯瑞斯公司 包含锌结合基因的取代的酪氨酸抑制剂

Also Published As

Publication number Publication date
BR112021007643A2 (pt) 2021-07-27
CN112955447A (zh) 2021-06-11
IL282588A (en) 2021-06-30
KR20210081353A (ko) 2021-07-01
EP3870580A1 (en) 2021-09-01
CA3116674A1 (en) 2020-04-30
JP7667568B2 (ja) 2025-04-23
AU2019368654B2 (en) 2025-02-27
US20250084076A1 (en) 2025-03-13
JP2022505645A (ja) 2022-01-14
WO2020083926A1 (en) 2020-04-30
DK3643713T3 (da) 2025-11-03
US20250101015A1 (en) 2025-03-27
EP3643713B1 (en) 2025-07-30
MX2021004568A (es) 2021-09-08
US12172993B2 (en) 2024-12-24
SG11202103142TA (en) 2021-05-28
AU2019368654A1 (en) 2021-05-06
EP3643713A1 (en) 2020-04-29
AU2019368654C1 (en) 2025-06-19
US20210387982A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
CN115667255B (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
JP7667568B2 (ja) 複素環キナーゼ阻害剤及びその使用
US12240869B2 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
US12139480B2 (en) 5-thiazolecarboxamide kinase inhibitor and uses thereof
US20230192701A1 (en) Bicyclic kinase inhibitors and uses thereof
IL297483A (en) Bifunctional compounds and their uses
JP6097770B2 (ja) フロピリジン誘導体
HK40062784A (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
AU2021410783A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
US20260070914A1 (en) Substituted pyrrolo[2,1-f][1,2,4]triazin-2-amines as cdk2 and cdk4 inhibitors
WO2025059429A1 (en) Modulators of bcl6 for use in a method of treating a cancer or an autoimmune disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20400108